TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Two University of Michigan cardiologists say gene therapies that could provide lasting control of conditions such as high cholesterol need careful scrutiny before wider use. Their JAMA Internal Medicine perspective highlights the limits of “one-and-done” treatment and questions about irreversible effects, delivery risks and long-term safety monitoring.
Two University of Michigan cardiologists are urging careful evaluation of gene-based treatments being explored for common conditions such as high cholesterol, warning that potentially lasting genetic changes require a different risk assessment from adjustable daily medicines. In a perspective published in JAMA Internal Medicine, Eric D. Smith and Venkatesh L. Murthy set out five questions clinicians and researchers should answer before genomic therapies are offered widely.
Genomic therapies can work by supplying a functional version of a gene, suppressing gene activity linked to disease, or changing a DNA sequence. Some are designed as single-administration treatments, unlike many conventional medicines, whose effects generally depend on continued use. Researchers are investigating whether these approaches could address widespread conditions including high cholesterol, heart disease, obesity and diabetes.
The authors caution that “one-and-done” does not necessarily mean lifelong benefit. Many therapies use modified viruses to deliver genetic instructions, and the immune system may respond to those delivery vehicles. That response can make it difficult or impossible to give the same treatment again if its effects diminish. Existing gene therapies generally target somatic cells, not reproductive cells, and are not intended to pass genetic changes to future generations.
Smith and Murthy propose weighing disease severity, available treatments, the suitability of the target tissue for a durable intervention, risks from delivering the therapy, and whether safety and effectiveness can be monitored over many years. The perspective is a framework for evaluating potential uses, not evidence that a gene-editing treatment has already replaced cholesterol medication or is ready for routine use.
Why Common Conditions Raise the Bar
The risk-benefit calculation changes when a treatment intended to make a lasting genetic change is used for a condition that already has treatment options. People with severe rare disorders may have few alternatives, while patients with common diseases such as high cholesterol may be able to use medicines that can be adjusted or stopped if circumstances change or side effects occur. A permanent intervention may offer less room to reverse course.
Scale also matters. Murthy warns that even a rare adverse effect could affect a substantial number of people if a treatment is given to millions. That makes evidence about long-term safety and the ability to detect delayed complications important before widespread use. For patients, the potential appeal of less frequent treatment must be weighed against uncertainties that do not apply in the same way to a medicine that can be discontinued.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Levoit Vital 100S-P Air Purifier for Home and Pets
As an affiliate, we earn on qualifying purchases.
From Rare Disorders to Common Disease
Gene therapies are already used for some serious illnesses, and the source report describes successes involving spinal muscular atrophy and sickle cell disease. More than 6,000 rare genetic disorders have been identified, but only a small proportion currently have targets considered treatable by these approaches, according to the report.
The research frontier is expanding from rare, severe conditions to diseases affecting far more people. Smith and Murthy’s perspective addresses what changes when genomic treatments are considered for those broader populations. The underlying distinction is not simply whether a therapy can alter genetic activity, but whether its expected benefit, durability and risks are appropriate for a particular disease and patient group.
“Smith argues that long-term monitoring cannot be treated as an afterthought.”
— Eric D. Smith, M.D., University of Michigan Health Frankel Cardiovascular Center
Long-Term Risks Still Need Tracking
The available source material does not establish that a gene-editing treatment for cholesterol or another common condition has been approved, has replaced standard medication, or can reliably provide lifelong benefits. The therapies discussed are an area of research, and the perspective focuses on how to evaluate them rather than reporting clinical results for a specific cholesterol treatment.
Clinical trials usually involve relatively small groups and limited follow-up, the authors note. Such studies may not detect very rare side effects or problems that take years to appear. It also remains uncertain how reliably safety and effectiveness can be tracked if treatment reaches a large population. The source report mentions patient registries as one possible monitoring tool but provides no further detail about a specific registry or monitoring plan.
Evidence and Monitoring Come Next
Researchers and clinicians will need evidence addressing the five factors in the authors’ framework as individual therapies are studied: how serious the target disease is, what alternatives exist, whether the target tissue suits a durable intervention, what risks come with delivery, and whether long-term follow-up is practical. Those answers will depend on the particular treatment and condition.
Smith’s emphasis on registries points to one way safety information could continue to be collected after treatment, alongside evidence from clinical trials. The source does not identify a specific next trial, regulatory decision or timeline for gene therapy aimed at cholesterol. For now, the key development is the proposed approach to assessing benefits and risks—not a confirmed change to care for people taking cholesterol medication.
Key Questions
Can gene editing already replace daily cholesterol medication?
The source report does not say that a gene-editing treatment has replaced cholesterol medication or is available for routine care. It describes research into genomic therapies for common diseases and a perspective on how to evaluate their risks.
Why might a one-time treatment be hard to repeat?
Many gene therapies use modified viruses to deliver genetic instructions. The immune system may recognize the delivery vehicle, potentially making a second administration difficult or impossible, even if the first treatment’s effects fade.
Would these treatments pass genetic changes to children?
The source says current gene therapies generally target somatic cells, which are not reproductive cells, and are not intended to create changes inherited by future generations. It distinguishes these treatments from germline editing.
What five factors do the cardiologists say should be weighed?
They identify disease severity, available treatments, the durability of the intended effect in the target tissue, delivery risks, and the ability to monitor safety and effectiveness over many years.
Why is long-term monitoring a concern?
Trials may be too small or too short to reveal very rare side effects or problems that develop years later. The authors say monitoring needs to remain part of how these therapies are introduced into medical practice.
Source: sciencedaily.com
